Dotamtate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Dotamtate
- Molecular weight
- 1,637.88
- Structure (SMILES)
- C(c1c2c([nH]c1)cccc2)[C@H]3NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@@H](NC([C@@H](Cc5ccccc5)NC(CN6CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC6)=O)=O)CSSC[C@@H](C(N[C@@H]([C@@H](C)O)C(O)=O)=O)NC(=O)[C@]([C@@H](C)O)(NC(=O)[C@H](CCCCN)NC3=O)[H]
- oxoreotide atexetan
- Oxoreotide Atexetan
- CAS registry numbers
- 2415661-92-4
- ChEMBL ID
- CHEMBL4300858
- InChIKey
- YXHMVRPWRYCPJP-CSBVGUNJSA-N
- PubChem compound IDs
- 135228365
- FDA ingredient codes (UNII)
- J2KEK56NRS
- First in class
- No
- Orphan designation
- No
Open Targets indications
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 1
- Calculated partition coefficient (XLogP)
- -4.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 101
- Molecular formula
- C65H91N17O16PbS2
- Monoisotopic mass
- 1431.64276229
- Natural product
- No
Related records
Trials (1)
In development for (1)
- Neuroendocrine carcinoma Phase 1